Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Antimicrobial Susceptibility of Clinical Isolates of Bacteroides fragilis Group Organisms Recovered from 2009 to 2012 in a Korean Hospital

  • Yim, Jisook (Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine) ;
  • Lee, Yangsoon (Department of Laboratory Medicine, Hanyang University College of Medicine) ;
  • Kim, Myungsook (Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine) ;
  • Seo, Young Hee (Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine) ;
  • Kim, Wan Hee (Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine) ;
  • Yong, Dongeun (Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine) ;
  • Jeong, Seok Hoon (Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine) ;
  • Lee, Kyungwon (Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine) ;
  • Chong, Yunsop (Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine)
  • Received : 2014.07.25
  • Accepted : 2014.10.30
  • Published : 2015.01.02
⟨ Previous Next ⟩

Abstract

Background: Periodic monitoring of antimicrobial resistance trends of clinically important anaerobic bacteria such as Bacteroides fragilis group organisms is required. We determined the antimicrobial susceptibilities of clinical isolates of B. fragilis group organisms recovered from 2009 to 2012 in a tertiary-care hospital in Korea. Methods: A total of 180 nonduplicate clinical isolates of B. fragilis group organisms were collected in a tertiary care hospital. The species were identified by conventional methods: the ATB 32A rapid identification system ($bioM{\acute{e}}rieux$, France) and the Vitek MS matrix-assisted laser desorption/ionization time-of-flight mass spectrometry ($bioM{\acute{e}}rieux$). Antimicrobial susceptibility was determined by the CLSI agar dilution method. Results: Imipenem and meropenem resistance rates were 0-6% for B. fragilis group isolates. The rate of resistance to piperacillin-tazobactam was 2% for B. fragilis and 0% for other Bacteroides species, but 17% for B. thetaiotaomicron isolates. High resistance rates to piperacillin (72% and 69%), cefotetan (89% and 58%), and clindamycin (83% and 69%) were observed for B. thetaiotaomicron and other Bacteroides spp. The moxifloxacin resistance rate was 27% for other Bacteroides spp. The $MIC_{50}$ and $MIC_{90}$ of tigecycline were $2-4{\mu}g/mL$ and $8-16{\mu}g/mL$, respectively. No isolates were resistant to chloramphenicol or metronidazole. Conclusions: Imipenem, meropenem, chloramphenicol, and metronidazole remain active against B. fragilis group isolates. Moxifloxacin and tigecycline resistance rates are 2-27% and 8-15% for B. fragilis group isolates, respectively.

Keywords

Acknowledgement

Supported by : Yonsei University College of Medicine

References

  1. Trevino M, Areses P, Penalver MD, Cortizo S, Pardo F, del Molino ML, et al. Susceptibility trends of Bacteroides fragilis group and characterisation of carbapenemase-producing strains by automated REP-PCR and MALDI TOF. Anaerobe 2012;18:37-43. https://doi.org/10.1016/j.anaerobe.2011.12.022
  2. Karlowsky JA, Walkty AJ, Adam HJ, Baxter MR, Hoban DJ, Zhanel GG. Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study. Antimicrob Agents Chemother 2012;56:1247-52. https://doi.org/10.1128/AAC.05823-11
  3. Nagy E, Urban E, Nord CE. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect 2011;17:371-9. https://doi.org/10.1111/j.1469-0691.2010.03256.x
  4. Fille M, Mango M, Lechner M, Schaumann R. Bacteroides fragilis group: trends in resistance. Curr Microbiol 2006;52:153-7. https://doi.org/10.1007/s00284-005-0249-x
  5. Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJ, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 2007;51:1649-55. https://doi.org/10.1128/AAC.01435-06
  6. Roh K, Kim S, Kim CK, Yum JH, Kim MS, Yong D, et al. Resistance trends of Bacteroides fragilis group over an 8-year period, 1997-2004, in Korea. Korean J Lab Med 2009;29:293-8. https://doi.org/10.3343/kjlm.2009.29.4.293
  7. Fernandez-Canigia L, Litterio M, Legaria MC, Castello L, Predari SC, Di Martino A, et al. First national survey of antibiotic susceptibility of the Bacteroides fragilis group: emerging resistance to carbapenems in Argentina. Antimicrob Agents Chemother 2012;56:1309-14. https://doi.org/10.1128/AAC.05622-11
  8. Lee Y, Park Y, Kim MS, Yong D, Jeong SH, Lee K, et al. Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. Antimicrob Agents Chemother 2010;54:3993-7. https://doi.org/10.1128/AAC.00481-10
  9. CLSI. Methods for Antimicrobial susceptibility testing of anaerobic bacteria; Approved standard, 8th ed. CLSI document M11-A8. Wayne, PA: Clinical and Laboratory Standards Institute, 2012.
  10. Seifert H and Dalhoff A. German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: results from the PRISMA study. J Antimicrob Chemother 2010;65:2405-10. https://doi.org/10.1093/jac/dkq321
  11. Brook I, Wexler HM, Goldstein EJ. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin Microbiol Rev 2013;26:526-46. https://doi.org/10.1128/CMR.00086-12
  12. The US Food and Drug Administration. FDA Approved Drug Products Label for TYGACIL, NDA no. 021821 (approved on 23/05/2013). http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021821s037lbl.pdf
  13. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1, 2013. http://www.eucast.org/clinical_breakpoints/
  14. Snydman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJ, et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Clin Infect Dis 2010;50(Sl):S26-33. https://doi.org/10.1086/647940
  15. Goldstein EJC and Citron DM. Resistance trends in antimicrobial susceptibility of anaerobic bacteria, part II. Clinical Microbiology Newsletter 2011;33:9-15. https://doi.org/10.1016/j.clinmicnews.2010.12.002
  16. Betriu C, Rodriguez-Avial I, Gomez M, Culebras E, Picazo JJ. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002). Diagn Microbiol Infect Dis 2005;53:221-3. https://doi.org/10.1016/j.diagmicrobio.2005.06.012
  17. Cho S, Chung HS, Lee Y, Kim M, Yong D, Jeong SH, et al. In vitro activities of ceftriaxone-sulbactam against major aerobic and anaerobic bacteria from clinical samples. Lab Med Online 2011;1:209-20. https://doi.org/10.3343/lmo.2011.1.4.7
  18. Wybo I, Van den Bossche D, Soetens O, Vekens E, Vandoorslaer K, Claeys G, et al. Fourth Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother 2014;69:155-61. https://doi.org/10.1093/jac/dkt344
  19. Brazier JS, Stubbs SL, Duerden BI. Metronidazole resistance among clinical isolates belonging to the Bacteroides fragilis group: time to be concerned? J Antimicrob Chemothery 1999;44:580-1. https://doi.org/10.1093/jac/44.4.580
  20. Lee K, Shin HB, Chong Y. Antimicrobial resistance patterns of Bacteroides fragilis group organisms in Korea. Yonsei Med J 1998;39:578-86. https://doi.org/10.3349/ymj.1998.39.6.578

Cited by

  1. Multicenter Study of Antimicrobial Susceptibility of Anaerobic Bacteria in Korea in 2012 vol.35, pp.5, 2015, https://doi.org/10.3343/alm.2015.35.5.479
  2. Cephalosporin Plus Metronidazole for Surgical Prophylaxis vol.19, pp.4, 2015, https://doi.org/10.1089/sur.2018.023
  3. Antimicrobial Susceptibility Patterns of Anaerobic Bacterial Clinical Isolates From 2014 to 2016, Including Recently Named or Renamed Species vol.39, pp.2, 2015, https://doi.org/10.3343/alm.2019.39.2.190
  4. Antimicrobial Resistance Profile and Nim Gene Detection among Bacteroides fragilis Group Isolates in a University Hospital in South India vol.11, pp.2, 2015, https://doi.org/10.4103/jgid.jgid_116_18
  5. Zerumbone Suppresses Enterotoxigenic Bacteroides fragilis Infection-Induced Colonic Inflammation through Inhibition of NF-κΒ vol.20, pp.18, 2019, https://doi.org/10.3390/ijms20184560
  6. Surveillance of antimicrobial resistance in recent clinical isolates of Gram-negative anaerobic bacteria in a Greek University Hospital vol.62, pp.None, 2015, https://doi.org/10.1016/j.anaerobe.2020.102173